The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U... Show more
The SPDR S&P Biotech ETF (XBI) is a passively managed fund that seeks to track the S&P Biotechnology Select Industry Index, a sub-industry slice of the broader S&P Total Market Index. Unlike many cap-weighted healthcare funds, XBI uses an equal-weighted methodology, which means each of its roughly 150-plus holdings is rebalanced toward a similar weight. This structure tilts the portfolio toward small- and mid-cap developers rather than letting a handful of mega-cap names dominate.
That design has a direct bearing on the ETF's future outlook. Equal weighting gives clinical-stage and early-commercial companies a proportionally larger role, so the fund's trajectory is closely tied to the health of biotech financing markets, deal activity, and binary data readouts. Top exposures have recently included names such as TWST (Twist Bioscience), MRNA (Moderna), NTRA (Natera), Iovance Biotherapeutics, AMGN (Amgen), BIIB (Biogen), United Therapeutics, ABBV (AbbVie), Halozyme, and GILD (Gilead Sciences).
Geographically, the portfolio is overwhelmingly concentrated in North America, with nearly all assets in the healthcare/biotechnology space. The fund carries a competitive expense ratio of roughly 0.35%, and its asset base has grown to the multi-billion-dollar range, reflecting renewed investor interest in the sector. Because the ETF holds a diversified basket of companies across oncology, immunology, rare disease, metabolic, and genetic-medicine platforms, its forward performance potential is shaped less by any single company and more by the aggregate health of biotech innovation and capital availability.
The macro backdrop has shifted in biotech's favor. After a restrictive period, the Federal Reserve's move toward lower rates has begun to ease the "cost of capital" burden that weighs disproportionately on pre-revenue drug developers. Lower rates support higher valuations for long-duration assets and encourage both equity issuance and deal-making, both central to the XBI universe.
At the sector level, the biotech cycle has shown signs of recovery from a cyclical trough marked by pricing pressure, regulatory uncertainty, and scarce capital. Analysts note that the sector remains relatively under-owned, and that valuations, while off their lows, still sit below historical medians in several segments. The S&P Biotechnology Select Industry Index's equal-weight construction means the fund is sensitive to shifts in risk appetite: when generalist investors rotate back into growth assets, small-cap biotech tends to outperform.
Inflation and the path of the U.S. dollar also matter. A stabilizing or moderating inflation environment that allows the Fed to keep easing would reinforce the financing window, while a stronger dollar can pressure the international revenue of larger, more diversified holdings. Policy developments at the FDA and the National Institutes of Health remain the most direct macro-regulatory swing factors, given their influence over approval timelines and research funding.
For investors seeking a data-driven view of where an asset may head next, Tickeron's Trend Prediction Engine offers an AI-powered forecasting tool designed to identify whether a stock, ETF, or other instrument may trend bullish, bearish, or sideways over the coming week or month. The engine helps users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments, supported by searchable prediction categories, historical context, and alert-oriented functionality. Used alongside fundamental research, it can add a timely, technical layer to the ETF forecast process for those monitoring XBI and the broader biotech complex.
Several structural forces underpin the longer-term trajectory of the biotech sector that XBI represents. An aging global population continues to expand demand for chronic-disease, oncology, and rare-disease therapies, supporting durable end-market growth. Meanwhile, advances in genetic medicine, cell therapy, and AI-enabled drug discovery are broadening the addressable pipeline of innovation and lowering discovery costs over time.
The pharmaceutical industry's looming patent cliff is another multi-year driver. As blockbuster drugs lose exclusivity, large-cap players are incentivized to acquire smaller developers, a dynamic that has historically supported valuations across the small- and mid-cap biotech space. Demographic and market-structure trends—including a healthier, more selective IPO environment and a rationalized public-company universe—may also reduce the supply/demand imbalance that once diluted investor attention.
At the same time, the equal-weighted nature of XBI means its long-term outlook is inherently more volatile than broad-market or large-cap healthcare funds. Investors should weigh the structural growth drivers of biotech innovation against the sector's sensitivity to interest-rate cycles, regulatory shifts, and binary clinical outcomes when forming their own view of the fund's future outlook.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NVIR | 38.38 | N/A | N/A |
| Horizon Kinetics Energy and Remediation ETF (NVIR) | |||
| BSCU | 16.25 | N/A | -0.03% |
| Invesco BulletShares 2030 Corporate Bond ETF (BSCU) | |||
| VCV | 9.21 | -0.02 | -0.22% |
| INVESCO CALIFORNIA VALUE MUNI Income TRUST | |||
| IBBQ | 34.11 | -0.37 | -1.07% |
| Invesco Nasdaq Biotechnology ETF (IBBQ) | |||
| DECT | 38.12 | -0.66 | -1.71% |
| AllianzIM U.S. Equity Buffer10 Dec ETF (DECT) | |||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DECT | 38.12 | -0.66 | -1.71% |
| AllianzIM U.S. Equity Buffer10 Dec ETF (DECT) | |||
| IBBQ | 34.11 | -0.37 | -1.07% |
| Invesco Nasdaq Biotechnology ETF (IBBQ) | |||
| VCV | 9.21 | -0.02 | -0.22% |
| INVESCO CALIFORNIA VALUE MUNI Income TRUST | |||
| BSCU | 16.25 | N/A | -0.03% |
| Invesco BulletShares 2030 Corporate Bond ETF (BSCU) | |||
| NVIR | 38.38 | N/A | N/A |
| Horizon Kinetics Energy and Remediation ETF (NVIR) | |||
A.I.dvisor indicates that over the last year, XBI has been closely correlated with SBIO. These tickers have moved in lockstep 94% of the time. This A.I.-generated data suggests there is a high statistical probability that if XBI jumps, then SBIO could also see price increases.
| Ticker / NAME | Correlation To XBI | 1D Price Change % | ||
|---|---|---|---|---|
| XBI | 100% | -0.63% | ||
| SBIO - XBI | 94% Closely correlated | -0.71% | ||
| BBC - XBI | 93% Closely correlated | N/A | ||
| BBP - XBI | 92% Closely correlated | -1.07% | ||
| IDNA - XBI | 88% Closely correlated | -1.59% | ||
| XPH - XBI | 85% Closely correlated | -1.26% | ||
More | ||||
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 80 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 50 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.